<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Osilodrostat" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Osilodrostat</book-part-id>
      <title-group>
        <title>Osilodrostat</title>
        <subtitle>Short Chapter</subtitle>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Oseltamivir" document-type="chapter">Oseltamivir</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Osimertinib" document-type="chapter">Osimertinib</related-object>
    </book-part-meta>
    <body>
      <p>
<italic toggle="yes">[Preliminary review chapter based on the FDA Product Labeling and Integrated Review only.]</italic>
</p>
      <sec id="Osilodrostat.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Osilodrostat.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Osilodrostat is an inhibitor of cortisol synthesis that is used in the treatment of Cushing disease not controlled by standard therapy. Osilodrostat therapy has not been linked to serum aminotransferase elevations during therapy or with instances of clinically apparent liver injury.</p>
        </sec>
        <sec id="Osilodrostat.Background">
          <title>Background</title>
          <p>Osilodrostat (oh sil&#x0201d; oh droe&#x02019; stat) is a small molecule inhibitor of cortisol synthesis used for patients with Cushing disease not eligible for or not cured by surgical resection. Osilodrostat lowers serum levels of cortisol and can decrease symptoms and signs of Cushing disease. In preregistration trials, osilodrostat reached the designated response rate in 86% of treated subjects. An important part of use of osilodrostat was the careful monitoring of cortisol and titration of the dose so as not to precipitate adrenal failure. Osilodrostat was approved in the United States in 2020 as therapy of patients with Cushing disease for whom surgery is not an option or has not been curative. Osilodrostat is available in tablets of 1, 5, and 10 mg under the brand name Isturisa. The recommended starting dosage is 2 mg twice daily, with subsequent careful titration of the dose in 1 to 2 mg increments at two-week intervals to achieve adequate suppression of serum cortisol levels. In registration trials that employed careful titration and monitoring, the most frequent adverse events were adrenal insufficiency (43%), fatigue (39%), nausea (37%), headache (31%), edema (21%), and lesser rates of arthralgia, rash, back pain, diarrhea, and dizziness. Uncommon but potentially serious adverse events included prolongation of the QTc interval, acute hypercortisolism, and adrenal failure. Monitoring of the electrocardiogram, blood pressure, serum cortisol and potassium levels, and signs of adrenal failure and hormonal changes (hirsutism, weight loss, worsening hypotension) is important. Osilodrostat should be prescribed only by health care personnel with knowledge and experience in managing hyper- and hypo-cortisolism.</p>
        </sec>
        <sec id="Osilodrostat.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In preregistration trials, mild, transient serum aminotransferase elevations occurred in 37 of 137 (27%) patients receiving osilodrostat for Cushing disease, but in only 8 (6%) patients were values above 3 times the upper limit of normal (ULN), and only 1 was above 5 times ULN (&#x0003c;1%). Furthermore, bilirubin levels remained normal and no patient developed symptomatic acute liver injury. In most instances, other causes for the liver test abnormalities were present including preexisting nonalcoholic fatty liver disease, gallstone disease, and hepatic metastases from the adrenal tumor. No patient required discontinuation of therapy for liver test abnormalities. Since its licensure and its more widescale clinical use, there have been no reports of acute liver injury attributed to osilodrostat.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Osilodrostat.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The causes of liver test abnormalities during osilodrostat therapy of refractory Cushing disease are often unrelated to the drug and are attributable to comorbidities of patients with hypercortisolism, such as fatty liver disease, gallstone disease, or malignancy.</p>
        </sec>
        <sec id="Osilodrostat.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The product label for osilodrostat does not recommend monitoring of routine liver tests during therapy with osilodrostat, but testing patients before starting therapy is appropriate because of the frequency of comorbidities including liver disease in patients with hypercortisolism. Rise in serum aminotransferase levels during therapy should trigger evaluation for other possible causes. Persistence of unexplained ALT levels above 3 times the ULN or appearance of symptoms of liver injury or jaundice should lead to at least temporary discontinuation and more careful monitoring.</p>
          <p>Drug Class: Endocrine Disease Agents</p>
        </sec>
      </sec>
      <sec id="Osilodrostat.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Osilodrostat &#x02013; Isturisa&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Endocrine Disease Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Osilodrostat">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Osilodrostat.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Osilodrostat.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Osilodrostat.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Osilodrostat.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Osilodrostat.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Osilodrostat.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Osilodrostat.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Osilodrostat</td>
                <td headers="hd_h_Osilodrostat.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">928134-65-0</td>
                <td headers="hd_h_Osilodrostat.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C13-H10-FN3</td>
                <td headers="hd_h_Osilodrostat.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="174561330" document-id-type="sid" document-type="summary" object-id="174561330" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Osilodrostat.BIBLIOGRAPHY">
        <title>BIBLIOGRAPHY</title>
        <p>References updated: 14 May 2024</p>
        <p>Abbreviations: ULN, upper limit of the normal range.</p>
        <p><bold><italic toggle="yes">[Short Chapter</italic></bold>
<italic toggle="yes">information is based largely on FDA Product Labeling and the FDA Integrated Review accessible from the FDA website</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm"><italic toggle="yes">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</italic></ext-link><italic toggle="yes">. All other references have not been fully reviewed and annotated.]</italic></p>
        <ref-list id="Osilodrostat.BIBLIOGRAPHY.reflist0">
          <ref id="Osilodrostat.REF.fda.2020">
            <mixed-citation publication-type="journal"><collab>FDA</collab>. <source>Integrated Review.</source>
<year>2020</year>.</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF2">
            <mixed-citation publication-type="web">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000MedR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000MedR.pdf</ext-link>
<annotation><p>
<italic toggle="yes">(FDA summary data on the safety and efficacy of osilodrostat, submitted in support of the application for approval as therapy of Cushing disease, mentions that 34% of 137 treated subjects in the registration trial had an ALT or AST elevation, but they were mostly mild, frequently attributable to co-existing conditions, only 2.9% were above 3 times the upper limit or normal (ULN), and no patient developed enzyme elevations with jaundice or symptoms).</italic>
</p></annotation>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.bertagna.2014.1375">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bertagna</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Pivonello</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fleseriu</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname>
<given-names>CE</given-names></string-name>, <etal>et al.</etal>
<article-title>LCI699, a potent 11&#x003b2;-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.</article-title>
<source>J Clin Endocrinol Metab.</source>
<year>2014</year>;<volume>99</volume>:<fpage>1375</fpage>-<lpage>83</lpage>.<pub-id pub-id-type="pmid">24423285</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.fleseriu.2016.138">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fleseriu</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pivonello</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Young</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hamrahian</surname>
<given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Molitch</surname>
<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Shimizu</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Osilodrostat, a potent oral 11&#x003b2;-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.</article-title>
<source>Pituitary.</source>
<year>2016</year>;<volume>19</volume>:<fpage>138</fpage>-<lpage>48</lpage>.<pub-id pub-id-type="pmid">26542280</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.duggan.2020.495">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Duggan</surname>
<given-names>S.</given-names></string-name>
<article-title>Osilodrostat: first approval.</article-title>
<source>Drugs.</source>
<year>2020</year>;<volume>80</volume>:<fpage>495</fpage>-<lpage>500</lpage>.<pub-id pub-id-type="pmid">32141023</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.pivonello.2020.748">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pivonello</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fleseriu</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Newell-Price</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bertagna</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Findling</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shimatsu</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname>
<given-names>F</given-names></string-name>, <etal>et al</etal>; <article-title>LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.</article-title>
<source>Lancet Diabetes Endocrinol.</source>
<year>2020</year>;<volume>8</volume>:<fpage>748</fpage>-<lpage>761</lpage>.<pub-id pub-id-type="pmid">32730798</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.osilodrostat_isturisa_for_cushings_disease.2021.21">
            <mixed-citation publication-type="journal"><collab>Osilodrostat (Isturisa) for Cushing's disease</collab>. <source>Med Lett Drugs Ther.</source>
<year>2021</year>;<volume>63</volume>(<issue>1617</issue>):<fpage>21</fpage>-<lpage>23</lpage>.<pub-id pub-id-type="pmid">33647005</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.chabre.2022.384">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chabre</surname>
<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cristante</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cracowski</surname>
<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Gay</surname>
<given-names>E</given-names></string-name>. <article-title>Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence.</article-title>
<source>Lancet Diabetes Endocrinol.</source>
<year>2022</year>;<volume>10</volume>:<fpage>384</fpage>-<lpage>385</lpage>.<pub-id pub-id-type="pmid">35597254</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.gadelha.2022.e2882">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gadelha</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bex</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Feelders</surname>
<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Heaney</surname>
<given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Auchus</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Gilis-Januszewska</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Witek</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Randomized trial of osilodrostat for the treatment of Cushing disease.</article-title>
<source>J Clin Endocrinol Metab.</source>
<year>2022</year>;<volume>107</volume>:<fpage>e2882</fpage>-<lpage>e2895</lpage>.<pub-id pub-id-type="pmid">35325149</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.fleseriu.2022.531">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fleseriu</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Newell-Price</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pivonello</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shimatsu</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Auchus</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Scaroni</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Belaya</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.</article-title>
<source>Eur J Endocrinol.</source>
<year>2022</year>;<volume>187</volume>:<fpage>531</fpage>-<lpage>541</lpage>.<pub-id pub-id-type="pmid">35980235</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.fleseriu.2022.959">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fleseriu</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Biller</surname>
<given-names>BMK</given-names></string-name>, <string-name name-style="western"><surname>Bertherat</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Young</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hatipoglu</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arnaldi</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>O'Connell</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).</article-title>
<source>Pituitary.</source>
<year>2022</year>;<volume>25</volume>:<fpage>959</fpage>-<lpage>970</lpage>.<pub-id pub-id-type="pmid">36219274</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.gadelha.2023.1236465">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gadelha</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname>
<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Witek</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bex</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Belaya</surname>
<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Turcu</surname>
<given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Feelders</surname>
<given-names>RA</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.</article-title>
<source>Front Endocrinol (Lausanne)</source>. <year>2023</year>;<volume>14</volume>:<elocation-id>1236465</elocation-id>.<pub-id pub-id-type="pmid">37680892</pub-id>
</mixed-citation>
          </ref>
          <ref id="Osilodrostat.REF.ferriere.2024.l1">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ferriere</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Salenave</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Puerto</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Young</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tabarin</surname>
<given-names>A</given-names></string-name>. <article-title>Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.</article-title>
<source>Eur J Endocrinol.</source>
<year>2024</year>;<volume>190</volume>:<fpage>L1</fpage>-<lpage>L3</lpage>.<pub-id pub-id-type="pmid">38123490</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Osilodrostat.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Osilodrostat+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Osilodrostat: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Osilodrostat">Trials on Osilodrostat: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
